BRAF and melanoma: In addition to the BRAF V600E/K mutant lines, Belvarafenib also inhibited most melanoma lines with a NRAS hotspot mutation (specifically Q61R, Q61K, Q61V, and Q61L) or the wild type for RAS/RAF proteins.